Bentall Operation in a Patient with Severe Hemophilia A and Marfan Syndrome by Use of a Biologic Composite Graft
| dc.contributor.author | Yildirim F. | |
| dc.contributor.author | Ozbakkaloglu A. | |
| dc.contributor.author | Ozturk T. | |
| dc.contributor.author | Tetik O. | |
| dc.date.accessioned | 2025-04-10T11:09:29Z | |
| dc.date.available | 2025-04-10T11:09:29Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | We describe a patient with severe hemophilia A and Marfan syndrome who underwent an elective Bentall operation. Because of the severe hemophilia, anticoagulation could not be given postoperatively; thus, a biologic Valsalva conduit graft was used. During the procedure, factor VIII was given as a bolus dose just before incision, then by continous infusion intraoperatively to maintain the factor VIII activity level between 200% and 300%. Minimal postoperative bleeding occurred. The infusion was continued postoperatively at a lower dose until all chest tubes, pacing wires, and invasive catheters were removed. The patient was discharged on postoperative day 7 without adverse events. © 2016 The Society of Thoracic Surgeons. | |
| dc.identifier.DOI-ID | 10.1016/j.athoracsur.2015.09.011 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/48780 | |
| dc.publisher | Elsevier USA | |
| dc.title | Bentall Operation in a Patient with Severe Hemophilia A and Marfan Syndrome by Use of a Biologic Composite Graft | |
| dc.type | Article |